Aptar completed the acquisition of a 64.6% stake in Voluntis for $61.5m.

Aptar, a drug delivery, consumer product dispensing and active material science solutions company, completed the acquisition of a 64.6% stake in Voluntis, a digitally augmented therapies to people with chronic conditions, for $61.5m. "Voluntis has established itself as a true innovator in digital therapeutics over the last decade with chronic disease management at the core of their offering. Combined with our existing device platforms, extensive research and development capabilities, and long-established relationships in the healthcare space, this strategic investment would accelerate Aptar’s future digital healthcare offerings and drive innovation that delivers life-changing and empowering support tools for patients around the globe," Stephan B. Tanda, Aptar President and CEO.